Martono DP, et al. - Among 282 patients initiating metformin and 89 patients initiating sulfonylurea derivatives, researchers investigated the added value of diabetes-related genetic risk scores to readily available clinical parameters in the forecast of HbA1c levels after glucose-regulating drugs were initiated. Only diabetes duration of more than 3 months when initiating metformin was linked to 2.7 mmol/mol higher HbA1c in the metformin prediction model. No significant clinical predictors have been identified for sulfonylurea derivatives. This investigation did not show a significant effect of type 2 diabetes-related genetic risk scores in general or the mechanism of action of the drugs for predicting inter-individual HbA1c variability in the short-term after metformin or sulfonylurea derivatives were started.